Hepatocellular Carcinoma
Conditions
Interventions
TCM group:He-Shu-Xiao-Ji pill combined with standard treatment strategy
CONTROL group:Standard treatment strategy
Sponsors
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with chronic hepatitis B and confirmed to be in CNLC stage I–III or BCLC stage A–C 2. Patients who have received standard treatment regimens recommended in the 2024 edition of the Clinical Practice Guidelines for the Diagnosis and Treatment of Primary Liver Cancer or the NCCN guidelines 3. Age between 18 and 75 years (inclusive) 4. Patients with liver function classified as Child-Pugh grade A or B 5. Patients who have voluntarily signed the informed consent form
Exclusion criteria
Exclusion criteria: 1. Patients with severe primary diseases of the heart kidneys hematopoietic system or other major organs 2. Patients with coexisting liver diseases such as other viral hepatitis severe alcoholic liver disease autoimmune liver disease or advanced nonalcoholic fatty liver disease 3. Patients with a known history of allergies or hypersensitivity to any components of traditional Chinese medicine 4. History of substance abuse or psychiatric disorders 5. Pregnant or breastfeeding women 6. Eastern Cooperative Oncology Group (ECOG) performance status score >1.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunity response factors;Quality of life score;Cancer biomarkers;Liver function classification;TCM symptom score; | — |
Countries
China
Contacts
Public ContactWANG JING
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
Outcome results
None listed